On Thursday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Kinross Gold Corporation (USA) (NYSE:KGC), Threshold Pharmaceuticals, Inc (NASDAQ:THLD), New Gold Inc. (USA) (NYSEMKT:NGD), Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR)
Kinross Gold Corporation (USA) (NYSE:KGC)’s shares dwindled -4.07%, and closed at $2.36. The stock has price to sale ratio of 0.79, however, price to book ratio is 0.56. With recent decline, the year-to-date (YTD) performance reflected a -16.31% decline below last year. During the past month the stocks lose -14.18%, bringing three-month performance to -8.88% and six-month performance to -31.59%. The mean recommendation of analysts for this stock is 2.70. (where 1=Buy, 5=Sale).
Kinross Gold Corporation, together with its subsidiaries, is engaged in mining and processing gold and silver ores. It is involved in the exploration, attainment, development, and operation of gold bearing properties. The company has operations in Canada, the United States, the Russian Federation, Brazil, Ecuador, Chile, Ghana, and Mauritania. As of December 31, 2013, its proven and probable mineral reserves comprised of 42.8 million ounces of gold, 44.8 million ounces of silver, and 1.4 billion pounds of copper. The company was founded in 1972 and is based in Toronto, Canada.
Threshold Pharmaceuticals, Inc (NASDAQ:THLD), declined -4.03%, and closed at $3.92. The company holds the market capitalization of $291.51M. For the last twelve months, the stock was able to keep return on equity at 84.50%, while return on assets at -26.70%, in response to its return on investment at 129.60%. Its 20-day moving average declined -11.48%, below 50-day moving average of -3.18%, above 200-day moving average of 4.56% from the latest market price of $3.92. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; and various earlier-stage clinical trials for therapeutic areas, counting advanced leukemias, multiple myeloma, advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors.
New Gold Inc. (USA) (NYSEMKT:NGD), dipped -3.99%, and closed at $3.61. The stock has the beta value of 0.09, and its volatility for the week is 5.44%, while for the month it is 6.10%. The company has the market capitalization of $1.83B. The company holds the book value per share of 5.34, whereas cash per share is 0.82. Price to book ratio remained 0.68, while price to sale ratio is 2.52. Analysts mean recommendation for the stock is said to be 2.70 (where 1=Buy, 5=sale).
New Gold Inc., a gold mining company, is engaged in the attainment, exploration, development, and operation of mineral properties. It primarily explores for gold, silver, and copper deposits. The company’s operating properties comprise a 100% interest in the Mesquite gold mine in California; the Cerro San Pedro gold-silver mine in the state of San Luis Potos in central Mexico; the New Afton gold-copper mine in British Columbia, Canada; and the Peak gold-copper mines in New South Wales, Australia. It also has exploration and development projects, counting a 100% interest in the Blackwater gold project in central British Columbia, Canada; a 30% interest in the El Morro gold-copper development project in the Atacama Region, Chile; and a 100% interest in the Rainy River gold project in Ontario, Canada.
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), dropped -3.98%, and closed at $5.79.The company has the market capitalization of $39.83B. The beta value of the stock is 1.88. On the other hand the stock’s volatility for the week is 4.24%, and for the month is 4.57%. The stock’s price to book ratio is 0.34, however price to sale ratio is 0.37. Analyst’s mean recommendation regarding this stock is 2.90. (where 1=Buy, 5=Sale).
Petroleo Brasileiro S.A.?Petrobras, together with its subsidiaries, engages in the exploration, exploitation, and production of oil and gas, and energy in Brazil and internationally. The company operates in four segments: Exploration and Production, Supply, Gas and Energy, and Distribution. The Exploration and Production segment engages in the exploration, development, and production of oil, liquefied natural gas, and natural gas in Brazil; and sells petroleum and bye products produced in natural gas processing plants. The Supply segment involves in the refining, logistic, transportation, and sale of oil products, petroleum, and alcohol. It also holds interests in petrochemical companies and fertilizer plants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
